Medicus Pharma advances SkinJect program with FDA submission targeting Gorlin Syndrome

Medicus Pharma (NASDAQ:MDCX) announced that it has submitted Protocol SKNJCT-005 to the US Food and Drug Administration (FDA) under its existing...
Open original source